Lu, Jiangjie
Zeng, Yong
Yi, Xiulin
Zhang, Hongmei
Zhu, Lin
Jiang, Lixin
Li, Jing
Zhou, Wei
Zhu, Hong
Xiong, Aijun http://orcid.org/0000-0001-5940-1587
Funding for this research was provided by:
the National major new drug development project (No. 2014ZX09101045003)
Article History
Received: 18 June 2020
Accepted: 8 October 2020
First Online: 9 November 2020
Ethics approval and consent to participate
: The study was approved by our IACUC. Recombinant insulin Lisargine injection (Lot No. M201605003) was obtained from Hefei Tianmai Biotechnology Development Co., Ltd., and it was used as test particle. Male SPF grade SD rats were purchased from Beijing Veitong Lihua Co., Ltd. All animal experiments were in compliance with the standard operating procedures for laboratory animals and laboratory animals specified by WuXi AppTec Institutional Animal Care and Use Committee (IACUC) Feeding and use guidelines and laboratory animal welfare requirements.
: Not applicable.
: There are no conflicts of interest to disclose.